 |
|
 |
 |
|
|
|
News Media
PRESS RELEASE - 4TH JUNE 2008 Sypharma Pty, Ltd., a privately owned Australian company based in Melbourne, announced today that it will be supplying an aseptically manufactured biological for Clinical Trials in Europe. The deal with Daval International Ltd, a UK based Biotech Company, has come about after regulatory approval was granted to provide Investigational Medicinal Product and Placebo for European trialing of new biological, AIMSPRO®. Sypharma has also signed an exclusive contract with Daval to develop the Veterinary form, Ceremben®, in the Australasian market and is sponsoring a trial, in conjunction with the University of Melbourne, for the treatment of endotoxaemia in Horses. See attached article - Aimspro SYPHARMA GAINS EXTENSION OF TGA LICENSE FOR BIOFORMULATION AND PROTEIN PURIFICATION Sypharma has now received notification from the TGA of its extension of license allowing us to offer contract protein purification services, as well as contract formulation and aseptic processing of solutions to GMP standard for clinical trials or commercial manufacture. Sypharma has developed this area to provide a personalised, fast service to the Australian Biotech Industry. Our manufacturing facility supplies both large and small volume parenteral solutions for clinical trial and commercial production. We have capabilities for aseptic manufacturing and filling of vials, as well as in-house terminal sterilization capabilities. In addition we offer chemical and microbiological analytical services, powder and cream manufacture as well as labelling and packaging services. Please call us to discuss how Sypharma can satisfy your future requirements. Contact: Jeremy White Ph: 03 9706 4913 Mob: 0412610444 Email: jeremy.white@sypharma.com.au
|
 |